Axxima Pharmaceuticals Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 20

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $17.8M

  • Investors
  • 1

Axxima Pharmaceuticals General Information

Description

Developer of antibiotic and antiviral drugs. The company develops small molecule compounds that block signal transduction pathways required by pathogens for their survival.

Contact Information

Website
www.axxima.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Am Klopfersitz 19
  • Martinsried
  • 82152 Munich
  • Germany
+49 089
Primary Industry
Consulting Services (B2B)
Acquirer
Vertical(s)
Corporate Office
  • Am Klopfersitz 19
  • Martinsried
  • 82152 Munich
  • Germany
+49 089

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Axxima Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 02-Mar-2005 $17.8M Completed Bankruptcy: Admin/Reorg
6. Bankruptcy: Admin/Reorg 01-Dec-2004 Completed Bankruptcy: Admin/Reorg
5. Later Stage VC (Series D) 01-Jun-2004 Completed Generating Revenue
4. Early Stage VC 19-Dec-2001 Completed Product Development
3. Grant 22-May-2001 Completed Product Development
2. Early Stage VC Completed Product Development
1. Early Stage VC Completed Product Development
To view Axxima Pharmaceuticals’s complete valuation and funding history, request access »

Axxima Pharmaceuticals Patents

Axxima Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20080194574-A1 Immunology diseases; autoimmune diseases; prion diseases; ipolar disorders; antiinflammatory agents; trnasplant rejection; antidiabetic agents; viricide against herpes virus, cytomegalo virus Inactive 19-Dec-2003
WO-2005058876-A1 Pyrazine derivatives as effective compounds against infectious diseases Inactive 16-Dec-2003
WO-2005040125-A1 Quinazoline derivatives for the treatment of herpesviral infections Inactive 06-Oct-2003
WO-2005026129-A1 Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases Inactive 15-Sep-2003
WO-2005023818-A2 Heterobicyclic compounds as pharmaceutically active agents Inactive 10-Sep-2003 C07D409/12
To view Axxima Pharmaceuticals’s complete patent history, request access »

Axxima Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Axxima Pharmaceuticals Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bear Stearns Health InnoVentures Management Venture Capital Minority
HBM Healthcare Investments Venture Capital Minority
Heidelberg Innovation Fonds Management Venture Capital Minority
LBBW Venture Capital Corporate Venture Capital Minority
Novartis Venture Fund Corporate Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Axxima Pharmaceuticals FAQs

  • When was Axxima Pharmaceuticals founded?

    Axxima Pharmaceuticals was founded in 1998.

  • Where is Axxima Pharmaceuticals headquartered?

    Axxima Pharmaceuticals is headquartered in Munich, Germany.

  • What is the size of Axxima Pharmaceuticals?

    Axxima Pharmaceuticals has 20 total employees.

  • What industry is Axxima Pharmaceuticals in?

    Axxima Pharmaceuticals’s primary industry is Consulting Services (B2B).

  • Is Axxima Pharmaceuticals a private or public company?

    Axxima Pharmaceuticals is a Private company.

  • What is the current valuation of Axxima Pharmaceuticals?

    The current valuation of Axxima Pharmaceuticals is .

  • What is Axxima Pharmaceuticals’s current revenue?

    The current revenue for Axxima Pharmaceuticals is .

  • How much funding has Axxima Pharmaceuticals raised over time?

    Axxima Pharmaceuticals has raised $41.8M.

  • Who are Axxima Pharmaceuticals’s investors?

    Bear Stearns Health InnoVentures Management, HBM Healthcare Investments, Heidelberg Innovation Fonds Management, LBBW Venture Capital, and Novartis Venture Fund are 5 of 9 investors who have invested in Axxima Pharmaceuticals.

  • When was Axxima Pharmaceuticals acquired?

    Axxima Pharmaceuticals was acquired on 02-Mar-2005.

  • Who acquired Axxima Pharmaceuticals?

    Axxima Pharmaceuticals was acquired by GPC Biotech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process